ATLANTA, Sept. 27, 2010 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq:ALIM), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the Company will present at the following investor conferences:
- Citi's 5 to be held October 5, 2010 at the Westin Boston Waterfront Hotel. Ken Green, Ph.D., Senior Vice President and Chief Scientific Officer, will participate in a panel discussion titled "Eye Diseases: Novel Therapies for Wet AMD, Retinal Vein Occlusion and Diabetic Macular Edema". The presentation is scheduled for October 5, 2010 at 8:00 a.m. ET.
- The 9 to be held October 5-6, 2010 at the Palace Hotel in San Francisco. Dan Myers, President and Chief Executive Officer, is scheduled to present on October 6, 2010 at 2:30 p.m. ET.
The Citi presentation will be webcast live and can be accessed at www.alimerasciences.com. For those who are not available to listen to the live broadcast, the presentation will be archived for 90 days.
About Alimera Sciences, Inc.
Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Presently the Company is focused on diseases affecting the back of the eye, or retina. Its advanced product candidate, Iluvien®, is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. Iluvien® is in development for the treatment of diabetic macular edema (DME), a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness.
CONTACT: Alimera Sciences, Inc. Richard S. Eiswirth, Jr., Chief Financial Officer 678.527.1750 ICR, Inc. Donald Ellis 925.253.1240
